Oo Thura Tun
Department of Biomedical Sciences, University of Illinois at Chicago, College of Medicine Rockford, Rockford, Illinois, USA.
Diabetes Obes Metab. 2025 Mar;27(3):1065-1078. doi: 10.1111/dom.16105. Epub 2024 Nov 27.
The term 'clinical cemetery' is frequently used to characterize ischaemic stroke, one of the leading causes of mortality and long-term morbidity globally. Over the past two decades, a number of novel therapies have been investigated for ischaemic stroke. However, aside from mechanical thrombectomy, the only FDA-approved prescription for treating ischaemic stroke is tissue plasminogen activator, which has a limited therapeutic period. Although post-stroke rehabilitation therapies are helpful in improving functional recovery, their benefits cannot be yielded promptly. Nowadays, drug repurposing might be an appealing approach to expanding therapeutic options for ischaemic stroke. During the last decade, metformin has been extensively researched as a potential repurposing medicine for ischaemic stroke, with a focus on both preventive and therapeutic approaches. With regard to the idea of repurposing metformin in ischaemic stroke, this review aims to compile the available data from pre-clinical and clinical trials, address and clarify any discrepancies, and offer solutions.
“临床死亡之地”这一术语常被用来描述缺血性中风，它是全球主要的死亡和长期致残原因之一。在过去二十年里，人们对多种治疗缺血性中风的新疗法进行了研究。然而，除了机械取栓术外，美国食品药品监督管理局（FDA）批准的唯一用于治疗缺血性中风的处方药是组织纤溶酶原激活剂，其治疗期有限。虽然中风后康复治疗有助于改善功能恢复，但无法迅速产生效果。如今，药物重新利用可能是一种拓展缺血性中风治疗选择的有吸引力的方法。在过去十年中，二甲双胍作为一种潜在的用于缺血性中风的重新利用药物受到了广泛研究，重点在于预防和治疗方法。关于在缺血性中风中重新利用二甲双胍的想法，本综述旨在汇总临床前和临床试验的现有数据，解决并澄清任何差异，并提供解决方案。
